This clinical trial is focused on studying Non-Small Cell Lung Cancer (NSCLC), a type of lung cancer that is common and can be challenging to treat, especially when it has spread to other parts of the body or is locally advanced. The study is comparing the effectiveness and safety of a medication called Furmonertinib with traditional platinum-based chemotherapy. Furmonertinib is a tablet taken orally, while platinum-based chemotherapy involves medications like Cisplatin, Carboplatin, and Pemetrexed, which are given through an infusion into a vein. These treatments are being tested as the first line of treatment for patients who have not received any prior systemic therapy for their advanced or metastatic NSCLC.

The purpose of the study is to determine how well Furmonertinib works compared to platinum-based chemotherapy in patients with a specific genetic mutation known as the EGFR exon 20 insertion mutation. This mutation affects the epidermal growth factor receptor, which plays a role in the growth and spread of cancer cells. The study will follow patients over time to see how long they live without their disease getting worse, which is known as progression-free survival (PFS). The study will also look at overall survival (OS), which is the time from the start of the study until death from any cause, and the objective response rate (ORR), which measures how many patients have a significant reduction in their cancer.

Participants in the study will be randomly assigned to receive either Furmonertinib or one of the platinum-based chemotherapy treatments. The study is open-label, meaning both the participants and the researchers know which treatment is being given. The trial will continue until 2028, allowing researchers to gather comprehensive data on the long-term effects and benefits of the treatments. This study aims to provide valuable insights into the best treatment options for patients with this specific type of lung cancer mutation.